Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > REGULATORY
REGULATORY
- MHLW to Improve Review System Based on Regulatory Science: PFSB Director General Yoshiyuki Kikura
February 22, 2012
- MHLW Warns Manufacturers to Take Steps to Ensure Proper Use of Anti-Influenza Drugs
February 22, 2012
- MHLW Issues Notification to Publicize FPMAJ’s Crude and Kampo Drug Standards
February 20, 2012
- MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
- Domestic Pharmaceutical Production Down 0.6% in 2010; First Decline in Six Years
February 20, 2012
- 105 Nu-lotan Generics from 35 Companies Approved for June Listing, 60% Pricing to Apply
February 16, 2012
- Medical Innovation Council Executive Meeting to Set Next 5-Year Plan by May
February 16, 2012
- MHLW to Revise Notification on GMP Inspection Requirements to Prepare for Participation in PIC/S
February 16, 2012
- PAFSC’s 2nd Committee on New Drugs to Discuss Approval for Pfizer Japan’s ALK Inhibitor Xalkori
February 16, 2012
- Osaka Prefecture Asking Korosho to Provide Pharmaceutical Strategy Consultation Services in Kansai Region
February 16, 2012
- Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
- Prof. Matsumoto of OPMI Stresses Need to Enhance Competitiveness of Pharmaceutical Industry
February 14, 2012
- MHLW Postpones Ban of Dispensing Points to October
February 14, 2012
- PAFSC’s First Committee on Drugs to Review Astellas’ Hyperphosphatemia Treatment on February 24
February 14, 2012
- Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
- CSIMC’S Medical Fee Reform Plan for FY2012 to Promote Faster Patient Discharge, Functional Specialization
February 13, 2012
- FY2012 Medical Fee Revision to Include New Measures to Promote Generic Drug Use
February 13, 2012
- Guidance Fee for Psychiatric Patients to Be Reduced from 55 to 44 Points When Prescribing 3 or More Drugs
February 10, 2012
- Delivery Price Settlement Rate Just 79.1% at End of December: MHLW
February 9, 2012
- Selection Process for Clinical Research Core Hospitals to Begin in Early March
February 9, 2012
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…